These results indicate that CD84 is likely an inhibitory receptor that is expressed on immune cells specifically during M. tuberculosis pathogenesis and promotes immunosuppressive signaling pathways, suggesting its suitability as a candidate target worthy of further investigation in the development of TB-specific checkpoint immunotherapies. The gene discussed is CD84; the disease is tuberculosis.